Assembly Biosciences Net Worth
Assembly Biosciences Net Worth Breakdown | ASMB |
Assembly Biosciences Net Worth Analysis
Assembly Biosciences' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Assembly Biosciences' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Assembly Biosciences' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Assembly Biosciences' net worth analysis. One common approach is to calculate Assembly Biosciences' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Assembly Biosciences' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Assembly Biosciences' net worth. This approach calculates the present value of Assembly Biosciences' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Assembly Biosciences' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Assembly Biosciences' net worth. This involves comparing Assembly Biosciences' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Assembly Biosciences' net worth relative to its peers.
Enterprise Value |
|
To determine if Assembly Biosciences is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Assembly Biosciences' net worth research are outlined below:
| Assembly Biosciences generated a negative expected return over the last 90 days | |
| Assembly Biosciences has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 7.16 M. Net Loss for the year was (61.23 M) with loss before overhead, payroll, taxes, and interest of (24.33 M). | |
| About 12.0% of the company shares are held by company insiders | |
| Latest headline from finance.yahoo.com: Broad coalition urges California Governor, legislative leaders and local elected officials to rebuild Los Angeles to countrys strongest building code |
Assembly Biosciences uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Assembly Biosciences. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Assembly Biosciences' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 27th of March 2024 Upcoming Quarterly Report | View | |
| 2nd of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 27th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Assembly Biosciences Target Price Consensus
Assembly target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Assembly Biosciences' target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 3 | Strong Buy |
Most Assembly analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Assembly stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Assembly Biosciences, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationAssembly Biosciences Target Price Projection
Assembly Biosciences' current and average target prices are 13.02 and 35.50, respectively. The current price of Assembly Biosciences is the price at which Assembly Biosciences is currently trading. On the other hand, Assembly Biosciences' target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Current Price
Assembly Biosciences Market Quote on 16th of February 2025
Target Price
Analyst Consensus On Assembly Biosciences Target Price
Know Assembly Biosciences' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Assembly Biosciences is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Assembly Biosciences backward and forwards among themselves. Assembly Biosciences' institutional investor refers to the entity that pools money to purchase Assembly Biosciences' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Bridgeway Capital Management, Llc | 2024-09-30 | 14.5 K | State Street Corp | 2024-09-30 | 12.8 K | Marshall Wace Asset Management Ltd | 2024-09-30 | 12.7 K | Citadel Advisors Llc | 2024-09-30 | 12.7 K | Palumbo Wealth Management Llc | 2024-12-31 | 11.4 K | Marquette Asset Management Inc. | 2024-12-31 | 9 K | Amundi | 2024-09-30 | 7.9 K | Jpmorgan Chase & Co | 2024-09-30 | 7 K | Barclays Plc | 2024-09-30 | 3 K | Armistice Capital, Llc | 2024-09-30 | 354 K | Vanguard Group Inc | 2024-09-30 | 200.5 K |
Follow Assembly Biosciences' market capitalization trends
The company currently falls under 'Micro-Cap' category with a current market capitalization of 82.76 M.Market Cap |
|
Project Assembly Biosciences' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.40) | (0.42) | |
| Return On Capital Employed | (0.76) | (0.80) | |
| Return On Assets | (0.40) | (0.42) | |
| Return On Equity | (1.71) | (1.63) |
When accessing Assembly Biosciences' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Assembly Biosciences' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Assembly Biosciences' profitability and make more informed investment decisions.
Please note, the presentation of Assembly Biosciences' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Assembly Biosciences' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Assembly Biosciences' management manipulating its earnings.
Evaluate Assembly Biosciences' management efficiency
Assembly Biosciences has return on total asset (ROA) of (0.3822) % which means that it has lost $0.3822 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.2051) %, meaning that it created substantial loss on money invested by shareholders. Assembly Biosciences' management efficiency ratios could be used to measure how well Assembly Biosciences manages its routine affairs as well as how well it operates its assets and liabilities. As of February 16, 2025, Return On Tangible Assets is expected to decline to -0.42. In addition to that, Return On Capital Employed is expected to decline to -0.8. At present, Assembly Biosciences' Other Current Assets are projected to increase significantly based on the last few years of reporting. The current year's Net Tangible Assets is expected to grow to about 107.5 M, whereas Total Assets are forecasted to decline to about 130.2 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 8.08 | 8.48 | |
| Tangible Book Value Per Share | 8.08 | 8.48 | |
| Enterprise Value Over EBITDA | (0.49) | (0.52) | |
| Price Book Value Ratio | 0.99 | 0.94 | |
| Enterprise Value Multiple | (0.49) | (0.52) | |
| Price Fair Value | 0.99 | 0.94 | |
| Enterprise Value | 24.8 M | 23.5 M |
Assembly Biosciences has shown resilience through effective management strategies. Our analysis examines how these strategies influence financial outcomes and investor returns which helps in understanding the stock's long-term potential.
Enterprise Value Revenue 0.4145 | Revenue | Quarterly Revenue Growth (1.00) | Revenue Per Share | Return On Equity |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Assembly Biosciences insiders, such as employees or executives, is commonly permitted as long as it does not rely on Assembly Biosciences' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Assembly Biosciences insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Schornstein Alexander over a year ago Purchase by Schornstein Alexander of 300000 shares of Assembly Biosciences | ||
Nicole White over a year ago Sale by Nicole White of 477 shares of Assembly Biosciences | ||
Schornstein Alexander over a year ago Assembly Biosciences exotic insider transaction detected | ||
Nicole White over a year ago Acquisition by Nicole White of 10000 shares of Assembly Biosciences subject to Rule 16b-3 | ||
Nicole White over a year ago Assembly Biosciences exotic insider transaction detected |
Assembly Biosciences Corporate Filings
| 14th of February 2025 Other Reports | ViewVerify | |
8K | 3rd of January 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 31st of December 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
| 23rd of December 2024 Other Reports | ViewVerify |
Assembly Biosciences Earnings Estimation Breakdown
The calculation of Assembly Biosciences' earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Assembly Biosciences is estimated to be -1.7175 with the future projection ranging from a low of -1.7175 to a high of -1.7175. Please be aware that this consensus of annual earnings estimates for Assembly Biosciences is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
-1.72 Lowest | Expected EPS | -1.72 Highest |
Assembly Biosciences Earnings Projection Consensus
Suppose the current estimates of Assembly Biosciences' value are higher than the current market price of the Assembly Biosciences stock. In this case, investors may conclude that Assembly Biosciences is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Assembly Biosciences' stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of December 2024 | Current EPS (TTM) | |
| 3 | 74.64% | -1.51 | -1.7175 | -6.89 |
Assembly Biosciences Earnings per Share Projection vs Actual
Actual Earning per Share of Assembly Biosciences refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering Assembly Biosciences predict the company's earnings will be in the future. The higher the earnings per share of Assembly Biosciences, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.Assembly Biosciences Estimated Months Earnings per Share
For an investor who is primarily interested in generating an income out of investing in entities such as Assembly Biosciences, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of Assembly Biosciences should always be considered in relation to other companies to make a more educated investment decision.Assembly Quarterly Analyst Estimates and Surprise Metrics
Earnings surprises can significantly impact Assembly Biosciences' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-11-06 | 2024-09-30 | -2.02 | -1.51 | 0.51 | 25 | ||
2024-08-08 | 2024-06-30 | -2.23 | -2.05 | 0.18 | 8 | ||
2024-05-08 | 2024-03-31 | -3.23 | -1.66 | 1.57 | 48 | ||
2024-01-31 | 2023-12-31 | -2.88 | -2.15 | 0.73 | 25 | ||
2023-11-08 | 2023-09-30 | -0.23 | -0.27 | -0.04 | 17 | ||
2023-08-09 | 2023-06-30 | -0.29 | -0.32 | -0.03 | 10 | ||
2023-05-04 | 2023-03-31 | -0.35 | -0.37 | -0.02 | 5 | ||
2023-03-22 | 2022-12-31 | -0.45 | -0.46 | -0.01 | 2 | ||
2022-11-08 | 2022-09-30 | -0.47 | -0.48 | -0.01 | 2 | ||
2022-08-09 | 2022-06-30 | -0.47 | -0.51 | -0.04 | 8 | ||
2022-05-12 | 2022-03-31 | -0.47 | -0.48 | -0.01 | 2 | ||
2022-03-10 | 2021-12-31 | -0.48 | -0.38 | 0.1 | 20 | ||
2021-11-04 | 2021-09-30 | -0.56 | -0.41 | 0.15 | 26 | ||
2021-08-05 | 2021-06-30 | -0.66 | -0.55 | 0.11 | 16 | ||
2021-05-06 | 2021-03-31 | -0.79 | -0.69 | 0.1 | 12 | ||
2021-02-25 | 2020-12-31 | -0.9 | -0.96 | -0.06 | 6 | ||
2020-11-05 | 2020-09-30 | -0.75 | -0.09 | 0.66 | 88 | ||
2020-08-05 | 2020-06-30 | -0.03 | 0.19 | 0.22 | 733 | ||
2020-05-07 | 2020-03-31 | -0.98 | -0.76 | 0.22 | 22 | ||
2020-03-04 | 2019-12-31 | -1.01 | -0.99 | 0.02 | 1 | ||
2019-11-07 | 2019-09-30 | -0.93 | -0.96 | -0.03 | 3 | ||
2019-08-05 | 2019-06-30 | -1.15 | -0.72 | 0.43 | 37 | ||
2019-05-09 | 2019-03-31 | -1.04 | -1.05 | -0.01 | 0 | ||
2019-02-28 | 2018-12-31 | -0.9 | -1.03 | -0.13 | 14 | ||
2018-11-08 | 2018-09-30 | -1.03 | -0.87 | 0.16 | 15 | ||
2018-08-08 | 2018-06-30 | -0.86 | -1.3 | -0.44 | 51 | ||
2018-05-07 | 2018-03-31 | -0.76 | -0.8 | -0.04 | 5 | ||
2018-03-08 | 2017-12-31 | -0.79 | -0.36 | 0.43 | 54 | ||
2017-11-01 | 2017-09-30 | -0.88 | -0.71 | 0.17 | 19 | ||
2017-08-09 | 2017-06-30 | -0.79 | -0.78 | 0.01 | 1 | ||
2017-05-08 | 2017-03-31 | -0.03 | -0.81 | -0.78 | 2600 | ||
2017-03-02 | 2016-12-31 | -0.67 | -0.67 | 0.0 | 0 | ||
2016-11-09 | 2016-09-30 | -0.67 | -0.67 | 0.0 | 0 | ||
2015-03-12 | 2014-12-31 | -0.57 | -0.38 | 0.19 | 33 | ||
2014-11-17 | 2014-09-30 | -0.48 | -1.33 | -0.85 | 177 | ||
2014-08-14 | 2014-06-30 | -0.65 | -0.52 | 0.13 | 20 | ||
2014-05-14 | 2014-03-31 | -0.7 | -0.9 | -0.2 | 28 | ||
2014-03-17 | 2013-12-31 | -1.4 | -0.29 | 1.11 | 79 | ||
2013-11-12 | 2013-09-30 | -1.3 | -1.25 | 0.05 | 3 | ||
2013-08-09 | 2013-06-30 | -1 | -1.2 | -0.2 | 20 | ||
2013-05-10 | 2013-03-31 | -1.1 | -1.1 | 0.0 | 0 | ||
2013-03-18 | 2012-12-31 | -1.54 | -1.4 | 0.14 | 9 | ||
2012-11-13 | 2012-09-30 | -1.94 | -2.05 | -0.11 | 5 | ||
2012-08-09 | 2012-06-30 | -2.89 | -2.95 | -0.06 | 2 | ||
2012-05-07 | 2012-03-31 | -2.51 | -3.3 | -0.79 | 31 | ||
2012-03-14 | 2011-12-31 | -5.42 | -8.9 | -3.48 | 64 | ||
2011-11-14 | 2011-09-30 | -2.5 | -2.5 | 0.0 | 0 | ||
2011-08-15 | 2011-06-30 | -2.55 | -4.85 | -2.3 | 90 | ||
2011-05-16 | 2011-03-31 | -0.87 | -1.9 | -1.03 | 118 |
Assembly Biosciences Corporate Management
| Nicole White | Chief Officer | Profile | |
| AO FRACP | CEO Director | Profile | |
| Adam Zlotnick | Chief CoFounder | Profile | |
| Amy CFA | Investor Consultant | Profile | |
| Uri MD | CoFounder Advisor | Profile |
Already Invested in Assembly Biosciences?
The danger of trading Assembly Biosciences is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Assembly Biosciences is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Assembly Biosciences. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Assembly Biosciences is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Assembly Biosciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Assembly Biosciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Assembly Biosciences Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Assembly Biosciences Stock: Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Assembly Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. For information on how to trade Assembly Stock refer to our How to Trade Assembly Stock guide.You can also try the Portfolio Volatility module to check portfolio volatility and analyze historical return density to properly model market risk.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Assembly Biosciences. If investors know Assembly will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Assembly Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (6.89) | Revenue Per Share | Quarterly Revenue Growth (1.00) | Return On Assets | Return On Equity |
The market value of Assembly Biosciences is measured differently than its book value, which is the value of Assembly that is recorded on the company's balance sheet. Investors also form their own opinion of Assembly Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Assembly Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Assembly Biosciences' market value can be influenced by many factors that don't directly affect Assembly Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Assembly Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Assembly Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Assembly Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.